These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35177911)

  • 1. The Evaluation of Meropenem Dosing Regimens Against ESBL-Producing
    Win EE; Htun KW; Tragulpiankit P; Tangtrakultham S; Montakantikul P
    Infect Drug Resist; 2022; 15():439-453. PubMed ID: 35177911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simulating moxalactam dosage for extended-spectrum β-lactamase-producing
    Huang C; Shi Q; Zheng B; Ji J; Ying C; Yu X; Wang H; Xiao Y
    Infect Drug Resist; 2019; 12():1199-1208. PubMed ID: 31190908
    [No Abstract]   [Full Text] [Related]  

  • 3. Meropenem dosing requirements against Enterobacteriaceae in critically ill patients: influence of renal function, geographical area and presence of extended-spectrum β-lactamases.
    Isla A; Canut A; Arribas J; Asín-Prieto E; Rodríguez-Gascón A
    Eur J Clin Microbiol Infect Dis; 2016 Mar; 35(3):511-9. PubMed ID: 26782093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Maximizing Css/MIC Ratio on Efficacy of Continuous Infusion Meropenem Against Documented Gram-Negative Infections in Critically Ill Patients and Population Pharmacokinetic/Pharmacodynamic Analysis to Support Treatment Optimization.
    Cojutti PG; Gatti M; Rinaldi M; Tonetti T; Laici C; Mega C; Siniscalchi A; Giannella M; Viale P; Pea F
    Front Pharmacol; 2021; 12():781892. PubMed ID: 34955851
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluation of Intravenous Fosfomycin Disodium Dosing Regimens in Critically Ill Patients for Treatment of Carbapenem-Resistant Enterobacterales Infections Using Monte Carlo Simulation.
    Leelawattanachai P; Wattanavijitkul T; Paiboonvong T; Plongla R; Chatsuwan T; Usayaporn S; Nosoongnoen W; Montakantikul P
    Antibiotics (Basel); 2020 Sep; 9(9):. PubMed ID: 32961833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colistin Dosing Regimens against
    Nguyen VTK; Montakantikul P; Tragulpiankit P; Houngsaitong J; Shuib MF
    Antibiotics (Basel); 2021 May; 10(5):. PubMed ID: 34067716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy and safety of colistimethate sodium in critical patients: an in vitro study by using of Monte Carlo simulation].
    Pan A; Mei Q; Yang T; Gao X; Lu H; Ye Y; Li J; Liu B
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2017 May; 29(5):385-389. PubMed ID: 28524024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent antibacterial activities of latamoxef (moxalactam) against ESBL producing Enterobacteriaceae analyzed by Monte Carlo simulation.
    Ito A; Tatsumi Y; Wajima T; Nakamura R; Tsuji M
    Jpn J Antibiot; 2014 Apr; 67(2):109-22. PubMed ID: 24956910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic/Pharmacodynamic (PK/PD) Simulation for Dosage Optimization of Colistin Against Carbapenem-Resistant
    Jitaree K; Sathirakul K; Houngsaitong J; Asuphon O; Saelim W; Thamlikitkul V; Montakantikul P
    Antibiotics (Basel); 2019 Aug; 8(3):. PubMed ID: 31443514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is Meropenem as a Monotherapy Truly Incompetent for Meropenem-Nonsusceptible Bacterial Strains? A Pharmacokinetic/Pharmacodynamic Modeling With Monte Carlo Simulation.
    Song X; Wu Y; Cao L; Yao D; Long M
    Front Microbiol; 2019; 10():2777. PubMed ID: 31849910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colistin plus Sulbactam or Fosfomycin against Carbapenem-Resistant
    Saelim W; Changpradub D; Thunyaharn S; Juntanawiwat P; Nulsopapon P; Santimaleeworagun W
    Infect Chemother; 2021 Mar; 53(1):128-140. PubMed ID: 34409786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a non-parametric modelling for meropenem in critically ill patients using Monte Carlo simulation.
    Idoate Grijalba AI; Aldaz Pastor A; Marquet P; Woillard JB
    Eur J Clin Pharmacol; 2019 Oct; 75(10):1405-1414. PubMed ID: 31338539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.
    Shea KM; Cheatham SC; Smith DW; Wack MF; Sowinski KM; Kays MB
    Ann Pharmacother; 2009 Nov; 43(11):1747-54. PubMed ID: 19809009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the pharmacodynamic profile of intravenous antibiotics against prevalent Gram-negative organisms collected in Colombia.
    Villegas MV; Briceno DF; Ruiz SJ; Furtado GH; Nicolau DP
    Braz J Infect Dis; 2011; 15(5):413-9. PubMed ID: 22230846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does Prolonged Infusion Time Really Improve the Efficacy of Meropenem Therapy? A Prospective Study in Critically Ill Patients.
    Zhao YC; Zou Y; Xiao YW; Wang F; Zhang BK; Xiang DX; Yu F; Luo H; Sandaradura I; Yan M
    Infect Dis Ther; 2022 Feb; 11(1):201-216. PubMed ID: 34748194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing the Dosing Regimens of Daptomycin Based on the Susceptible Dose-Dependent Breakpoint against Vancomycin-Resistant Enterococci Infection.
    Santimaleeworagun W; Changpradub D; Thunyaharn S; Hemapanpairoa J
    Antibiotics (Basel); 2019 Nov; 8(4):. PubMed ID: 31795437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Potential Use of Ceftazidime-Avibactam Against Carbapenem Resistant
    Nasomsong W; Nulsopapon P; Changpradub D; Pongchaidecha M; Pungcharoenkijkul S; Juntanawiwat P; Simsiriporn W; Santimaleeworagun W
    Drug Des Devel Ther; 2021; 15():3095-3104. PubMed ID: 34295150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States.
    Koomanachai P; Bulik CC; Kuti JL; Nicolau DP
    Clin Ther; 2010 Apr; 32(4):766-79. PubMed ID: 20435246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic/Pharmacodynamic Adequacy of Novel β-Lactam/β-Lactamase Inhibitors against Gram-Negative Bacterial in Critically Ill Patients.
    Han R; Sun D; Li S; Chen J; Teng M; Yang B; Dong Y; Wang T
    Antibiotics (Basel); 2021 Aug; 10(8):. PubMed ID: 34439043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal dosing regimen of biapenem in Chinese patients with lower respiratory tract infections based on population pharmacokinetic/pharmacodynamic modelling and Monte Carlo simulation.
    Dong J; Xiong W; Chen Y; Zhao Y; Lu Y; Zhao D; Li W; Liu Y; Chen X
    Int J Antimicrob Agents; 2016 Mar; 47(3):202-9. PubMed ID: 26895604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.